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Abstract
Bryostatin-1 inhibits acute myeloid leukemia (AML) in
vitro at doses that stimulate the growth of normal
hematopoietic progenitors. Although bryostatin-1 has
a number of distinct biological activities, those
specifically responsible for its antileukemic activity are
unclear. We found that bryostatin-1 (10
8 M) inhibited
cell cycling at G1, induced phenotypic evidence of
differentiation, and limited the clonogenic growth of
both AML cell lines and patient specimens. This
activity was markedly enhanced by granulocyte/
macrophage-colony stimulating factor, whereas growth
factor-neutralizing antibodies completely inhibited both
the differentiating and antileukemic activities of
bryostatin-1. Cell cycle inhibition and growth factors
were also required for the differentiating activities of
two unrelated agents, hydroxyurea and phenylbutyrate.
These data suggest that many pharmacological
differentiating agents require both cell cycle arrest and
lineage-specific growth factors for full activity and may
explain why these agents have demonstrated only
limited clinical efficacy.
Introduction
Induction therapy with standard cytotoxic chemotherapeutic
agents produces complete remissions in the majority of pa-
tients diagnosed with AML.
4 Unfortunately, most of these
patients relapse and eventually die from their disease (1).
Efforts to increase the overall and disease-free survival rates
in AML have focused on improving the efficacy of postrem-
ission consolidation by administering dose-intensified cyto-
toxic chemotherapeutic agents alone or combined with au-
tologous or allogeneic stem cell support (2, 3). These
approaches have improved the clinical outcomes for se-
lected subsets of patients with AML but have also increased
the incidence of treatment-related morbidity and mortality;
therefore, novel agents and therapeutic modalities are
needed.
Bryostatin-1 is a promising agent in the treatment of AML.
Numerous in vitro studies have shown that bryostatin-1 has
inhibitory effects on both AML cell lines and patient samples,
whereas it stimulates the growth of normal hematopoietic
cells (4–9). The antileukemic activity of bryostatin-1 is also
enhanced by a number of compounds, including the cyto-
toxic chemotherapeutic agent ara-C and the myeloid growth
factor GM-CSF (10, 11). Although it is not surprising that
bryostatin-1 augments the cytotoxic effects of ara-C be-
cause each has antitumor activity on its own, the interaction
between bryostatin-1 and GM-CSF is somewhat surprising,
given that GM-CSF alone may increase the proliferation and
survival of AML cells both in vitro and in vivo (12–14).
The effects of bryostatin-1 are mediated by PKC. Acute
exposure to bryostatin-1 activates PKC, whereas chronic
treatment results in the down-regulation of PKC through the
ubiquitination and subsequent proteolysis of the cPKC sub-
unit (15–18). Although its cellular target has been well delin-
eated, bryostatin-1 has a number of distinct biological prop-
erties, and the actual mechanism responsible for its
antileukemic activity is largely speculative. Similar to the
prototypical PKC activator, phorbol ester, bryostatin-1 in-
duces the differentiation of AML cell lines (19–21). It also
inhibits cell proliferation by blocking cell cycling at G1 or both
G1 and G2-M that is mediated by the inhibition of cdk2 and
the up-regulation of the cdk inhibitors, p21
cip1/waf1 and
p27
kip1 (20, 22). Furthermore, bryostatin-1 has potent immu-
noregulatory properties. It induces the expression of IL-2
receptors on CD4
 and CD8
 T cells and enhances IL-2-
mediated activation of in vivo primed CTLs (23, 24). To better
define the cellular processes responsible for its antileukemic
activity, we studied the effects of bryostatin-1, alone and in
combination with GM-CSF, on AML cell lines and patient
specimens.
Results
Effects of Bryostatin-1 on AML Cells. We initially exam-
ined the effect of bryostatin-1 on the growth, self-renewal,
and differentiation of AML cells. We have demonstrated pre-
viously that bryostatin-1 inhibits the growth of myeloid leu-
kemia at concentrations between 10
9 and 10
7 M, with
10
8 M generally being the most active (6). At this concen-
tration, bryostatin-1 inhibited the proliferation of the human
AML cell lines U937 and HL60 associated with cell cycle
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assessed by trypan blue dye exclusion or flow cytometric
analysis of apoptosis (data not shown). We also studied the
effect of bryostatin-1 on the self-renewal of each cell line by
examining clonogenic AML growth in methylcellulose. After
120 h of treatment in liquid culture and before plating, cells
were washed to remove bryostatin-1 and ensure that colony
formation reflected clonogenic potential at the end of the
treatment period in liquid culture, rather than a direct anti-
proliferative effect of bryostatin-1 during the subsequent
growth in methylcellulose. Compared with untreated cells,
the clonogenic recovery of both cell lines was modestly
inhibited by bryostatin-1 alone (Fig. 1). Because the inhibition
of clonogenic growth without direct cytotoxicity could result
from the induction of terminal differentiation, cells were ex-
amined for evidence of myeloid differentiation. Previous
studies have demonstrated that U937 cells primarily develop
monocytic features, whereas HL60 cells can undergo either
granulocytic or monocytic differentiation (25, 26). Bryosta-
tin-1 modestly induced the phenotypic differentiation of both
U937 and HL60 cells, as evidenced by nuclear condensation
on morphological examination (data not shown) and en-
hanced expression of the monocytic cell surface antigens
CD11b and CD14 (Fig. 2).
Although both U937 and HL60 cells express functional
GM-CSF receptors (27), GM-CSF alone had little effect on
the growth or differentiation of either cell line as assessed by
clonogenic growth (Fig. 1), morphology (data not shown), or
CD11b and CD14 expression (Fig. 2). However, the addition
of GM-CSF to bryostatin-1 further inhibited the clonogenic
growth of both U937 and HL60 cells when compared with
bryostatin-1 alone (Fig. 1). This effect was not attributable to
enhancement of the antiproliferative activity of bryostatin-1
because the addition of GM-CSF had no effect on the cell
cycle profile of U937 cells (Table 1). This combination also
induced further phenotypic evidence of differentiation, with
the majority of cells resembling mature monocytes (data not
shown) and displaying enhanced CD11b and CD14 expres-
sion on U937 cells and CD14 on HL60 cells (Fig. 2). Further-
more, examination of CD11b expression demonstrated that
Table 1 Cell cycle inhibition by pharmacological differentiating agents
U937 cells were incubated alone or in the presence of byrostatin-1 (10 nM) with or without GM-CSF (200 units/ml), hydroxyurea (100 g/ml), or
phenylbutyrate (1.5 mM) for 48 h and then analyzed for cell cycle distribution. Results are provided as the percentage of total cells and represent the mean 
SE of five separate experiments.
Cell cycle
phase Control Bryostatin Bryostatin 
GM-CSF Hydroxyurea Phenylbutyrate
G0-G1 31.8  1.6 47.7  7.4 48.1  3.2 19.5  2.3 53.9  15
S 61.2  3.3 39.3  16 39.7  5.5 76.3  3.0 39.0  19
G2-M 7.0  1.7 10.2  6.3 12.2  4.1 3.0  0.6 4.4  1.8
Fig. 1. Effects of bryostatin-1 and GM-CSF on AML cell line clonogenic
growth. U937 (A) and HL60 (B) cells were incubated in the absence
(Control) or presence of bryostatin-1 (10
8 M) with or without GM-CSF
(200 units/ml). Results represent the percentage of clonogenic recovery
compared with untreated control samples and are the means of five
separate experiments; bars, SE. P  0.001 was accessed by ANOVA for
the comparison of the treatment groups in both the U937 (A) and HL60 (B)
cells.
Fig. 2. Effects of bryostatin-1 and GM-CSF on cell surface antigen ex-
pression by AML cell lines. U937 (A) and HL60 (B) cells were incubated for
120 h in the absence (Control) or presence of bryostatin-1 (Bryo, 10
8 M)
with or without GM-CSF (200 units/ml) and then assessed for the surface
expression of CD11b and CD14 by flow cytometry. Results represent
means of five separate experiments; bars, SE. Ps were determined by
ANOVA for the comparison of all treatment groups for both CD11b and
CD14 expression.
276 Growth Factor-driven Differentiation of Myeloid Leukemiathe entire population of U937 cells underwent phenotypic
differentiation when treated with bryostatin-1 and GM-CSF
(Fig. 3A).
The combination of GM-CSF and bryostatin-1 was also
tested against primary samples derived from seven newly
diagnosed patients with AML; patients with AML-M3 (APL)
were excluded because this subtype of AML readily differ-
entiates in response to a number of pharmacological differ-
entiating agents (28). Patient characteristics are described in
Table 2. Neither bryostatin-1 nor GM-CSF alone induced
significant evidence of differentiation of primary AML cells as
assessed by morphological examination (Fig. 4), surface an-
tigen expression (Fig. 5A), or inhibition of clonogenic AML
growth (Fig. 5B). However, as with the AML cell lines, the
combination of bryostatin-1 and GM-CSF induced morpho-
logical evidence of myeloid differentiation in all cases with a
decrease in the nuclear:cytoplasmic ratio, nuclear conden-
sation with the loss of nucleoli, and the appearance of cyto-
plasmic granulation and vacuoles (Fig. 4). The expression of
the monocytic antigens CD11b and CD14 varied consider-
ably among patient specimens, particularly in the samples
derived from the four patients with relatively undifferentiated
M1-AML; however, all specimens demonstrated evidence of
granulocytic differentiation with increased expression of
CD15 following the addition of GM-CSF to bryostatin-1 (Fig.
5A; P  0.003). As in the cell lines, the entire population of
blasts underwent phenotypic differentiation (Fig. 3B). The
combination of bryostatin-1 and GM-CSF also significantly
inhibited the clonogenic recovery of primary AML samples
(Fig. 5B; P  0.002).
Requirement of Growth Factors for the Activity of
Bryostatin-1. Although its antileukemic activity was signifi-
cantly enhanced by GM-CSF, bryostatin-1 induced a modest
degree of differentiation on its own. To determine whether
this activity was dependent on growth factors present in the
FBS or resulting from autocrine secretion by the leukemia
cells, U937 cells were treated with bryostatin-1 in the pres-
Fig. 3. Flow cytometry histograms of cell sur-
face antigen expression by AML. A, U937 cells
were incubated in the presence of GM-CSF
(200 units/ml) and bryostatin-1 (10
8 M), hy-
droxyurea (100 g/ml), or phenylbutyrate (1.5
mM) for 120 h and analyzed for CD11b expres-
sion by flow cytometry. B, AML blasts from
patient number 2 were incubated with bryosta-
tin-1 (10
8 M) and GM-CSF (200 units/ml) for
120 h and then evaluated for CD15 expression.
Experimental groups are depicted by solid lines,
whereas dotted lines represent untreated con-
trol cells. Cell numbers of all groups remained
constant throughout the 5-day incubation.
Table 2 Clinical characteristics of seven cases of AML
Case Age Sex FAB class
a Cytogenetics
b
1 73 F M1 46XX
2 22 M M1 46XY
3 22 F M1 46XX
4 65 M M1 Complex
c
5 63 M M5 46XY
6 74 F M4 46XX
7 65 M M5 Complex
a French-American-British subtype based on cytochemistry.
b Metaphase karyotype.
c 3 clonal karyotypic abnormalities.
Fig. 4. Effects of bryostatin-1 and GM-CSF on the morphology of AML
blasts. Isolated AML blasts were incubated for 120 h in the absence
(Control) or presence of bryostatin-1 (10
8 M) with or without GM-CSF
(200 units/ml). Results represent Wright-Giemsa stained cytospin prepa-
rations from a representative patient. 400.
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IL-3. Antibodies against both GM-CSF and IL-3 were used
because U937 cells express both types of receptors, and
there is significant cross-talk between their intracellular sig-
naling pathways (27, 29, 30). Antibodies against human GM-
CSF and IL-3 have been shown to block the activity of these
growth factors present in FBS (31). These antibodies signif-
icantly, and almost completely, abrogated both the up-
regulation of CD11b (Fig. 6A; P  0.001) and the inhibition of
clonogenic leukemia growth (Fig. 6B; P  0.001) induced by
bryostatin-1 alone.
Effect of GM-CSF on the Activity of Other Differentiat-
ing Agents. Similar to bryostatin-1, many other pharmaco-
logical agents that induce tumor cell differentiation in vitro
are potent cell cycle inhibitors, regardless of their cellular
targets (32–34). Standard chemotherapeutic agents, such as
ara-C and hydroxyurea, also inhibit cell cycling and promote
differentiation of leukemia cells when used at low doses
(35–38). Furthermore, signals that induce cell cycle arrest
often are associated with cellular differentiation, whereas
those that promote cell cycle progression usually block cel-
lular differentiation (39, 40). To investigate the roles of cell
cycle inhibition and growth factors in the activity of other
differentiating agents, we examined the effects of cytostatic
doses of the chemotherapeutic agent hydroxyurea and the
pharmacological differentiating agent phenylbutyrate, alone
and in combination with GM-CSF. Hydroxyurea interferes
with deoxyribonucleotide synthesis and inhibits the cell cycle
at S-phase (41, 42), whereas phenylbutyrate inhibits histone
deacetylation and induces a G1 arrest (43, 44).
Hydroxyurea and butyrates have also been reported to
induce the differentiation of U937 cells (45–48). Growth
curves demonstrated that hydroxyurea at 100 g/ml and
phenylbutyrate at 1.5 mM inhibited the growth of U937 cells
without inducing apoptosis (data not shown), and DNA con-
tent analysis revealed that cell cycling was inhibited at the
expected points (Table 1). As with bryostatin-1, both hy-
droxyurea and phenylbutyrate inhibited clonogenic leukemia
growth that was enhanced by the addition of GM-CSF (Fig.
7A). Hydroxyurea and phenylbutyrate also induced pheno-
typic differentiation of the entire population of U937 cells, as
evidenced by the up-regulation of CD11b, that was aug-
mented by GM-CSF (Figs. 3A and 7B). Similar to bryosta-
tin-1, neither drug affected clonogenic growth or phenotypic
differentiation at doses (bryostatin-1, 5  10
10 M;h y -
droxyurea, 50 g/ml; phenylbutyrate, 1m M) that failed to
inhibit proliferation and induce cell cycle arrest (data not
shown). Furthermore, neutralizing antibodies against GM-
CSF and IL-3 were effective in limiting the differentiation of
U937 cells mediated by both hydroxyurea and phenylbu-
tyrate, as demonstrated by the inhibition of CD11b expres-
sion (Fig. 8A) as well as the decrease in clonogenic growth
(Fig. 8B).
Effect of Cytostatic Agents  GM-CSF on Normal He-
matopoietic Progenitors. Given the potent antileukemic
activity of combining any of the pharmacological agents
tested with GM-CSF, we examined their effects on normal
hematopoietic progenitors. Incubation of normal bone mar-
row mononuclear cells with any of the pharmacological
agents combined with GM-CSF yielded only limited inhibition
in CFU-GM growth (Fig. 9).
Fig. 5. Effects of bryostatin-1  GM-CSF on primary AML samples.
Isolated AML blasts were incubated for 120 h in the absence (Control)o r
presence of bryostatin-1 (10
8 M) with or without GM-CSF (200 units/ml)
and assayed for CD15 expression (A) and clonogenic growth (B). Results
represent the means for the seven patient specimens; bars, SE. P  0.002
was determined by ANOVA for the comparison of all treatment groups for
both CD15 expression (A) and clonogenic growth (B).
Fig. 6. Role of growth factors in the activity of bryostatin-1. U937 cells
were incubated for 120 h in the absence (Control) or presence of bryo-
statin-1 (10
8 M) along with neutralizing antihuman GM-CSF (0.1 mg/ml)
and antihuman IL-3 (0.15 mg/ml) or nonbinding isotypic control antibodies
and assayed for CD11b expression (A) and clonogenic growth (B). All
results represent the means of three separate experiments; bars, SE. P 
0.001 was determined by the paired Student’s t test for the comparison of
bryostatin-1  isotypic control antibodies and bryostatin-1  growth
factor blocking antibodies for both CD11b expression (A) and clonogenic
growth (B).
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We found that bryostatin-1 inhibited the clonogenic growth
of AML cell lines and patient samples. This was not attrib-
utable to the induction of cellular apoptosis nor a direct
cytostatic effect of bryostatin-1 on AML cells because it was
removed before assessing clonogenic growth. The loss of
leukemic clonogenic capacity was associated with pheno-
typic evidence of myeloid maturation, suggesting that cells
lost the ability to replicate as a result of terminal differentia-
tion. The addition of GM-CSF markedly enhanced the anti-
leukemic effects of bryostatin-1 as well as two other unre-
lated agents, hydroxyurea and phenylbutyrate. Importantly,
the activity of bryostatin-1 combined with GM-CSF was seen
not only in cell lines but also in all clinical AML samples
tested. Another report has likewise described the differenti-
ation of AML blasts using a combination of bryostatin-1 and
cytokines (49). Outside of APL, the induction of differentia-
tion in clinical AML samples has generally been unsuccessful
(50), especially in the M1 subtype of AML that constituted the
majority of cases in our study. Although enhanced leukemic
differentiation resulting from the combined use of growth
factors and pharmacological differentiating agents, such as
ATRA and vitamin D, has been described (51–53), these
studies did not examine the relative roles of growth factors
and pharmacological differentiating agents. We found that
neutralizing antibodies directed against GM-CSF and IL-3
limited the activity of all of the pharmacological agents
tested, and in the case of bryostatin-1, completely blocked
its antileukemic effects. These data suggest that pharmaco-
logical differentiating agents are not sufficient for the induc-
tion of tumor cell terminal differentiation but require the ac-
tivity of growth factors.
Lineage-specific growth factors, such as GM-CSF, have
pleiotropic effects on both malignant and normal cells, that
include enhancing proliferation, promoting cell survival, and
inducing differentiation. The net clinical effect of growth fac-
tors on tumor cell growth is determined by the relative con-
tribution of each of these activities. Tumor progression may
result from the enhancement of tumor cell proliferation or
Fig. 7. Effects of cytostatic agents on U937 cells. U937 cells were incu-
bated in the absence (Control) or presence of hydroxyurea (100 g/ml) or
phenylbutyrate (1.5 mM) with or without GM-CSF (200 units/ml) for 120 h
and then assessed for clonogenic leukemia growth (A) and CD11b ex-
pression (B). Results represent means of five separate experiments; bars,
SE. Ps are as determined by ANOVA for the comparison of all treatment
groups.
Fig. 8. Role of growth factors on the differentiating activity of pharma-
cological differentiating agents. U937 cells were incubated for 120 h in the
absence (Control) or presence of hydroxyurea (100 g/ml) or phenylbu-
tyrate (1.5 mM) along with neutralizing antihuman GM-CSF (0.1 mg/ml) and
antihuman IL-3 (0.15 mg/ml) or nonbinding isotypic control antibodies and
assessed for CD11b expression (A) and clonogenic growth (B). All results
represent the means of three separate experiments; bars, SE. Ps compare
agents treated with blocking antibodies or control antibodies by the paired
Student’s t test.
Fig. 9. Effects of combining GM-CSF and cytostatic agents on normal
hematopoiesis. Bone marrow mononuclear cells from normal donors were
treated for 120 h in the absence (Control) or presence of hydroxyurea (HU,
100 g/ml), phenylbutyrate (PB, 1.5 mM), or bryostatin-1 (Bryo, 10
8 M)
with or without GM-CSF (200 units/ml) and then washed and plated in
methylcellulose. Results are the means of three separate experiments;
bars, SE. Ps are as determined by ANOVA for the comparison of all
treatment groups.
279 Cell Growth & Differentiationsurvival, whereas the preferential induction of terminal dif-
ferentiation and subsequent loss of self-renewal capacity
may lead to the exhaustion or eradication of the neoplastic
clone. The stimulatory effects of myeloid growth factors on
leukemic cell growth may predominate in most settings;
however, we and others have demonstrated previously that
GM-CSF preferentially enhances the differentiation, rather
than proliferation, of malignant progenitors in CML (54–56).
Therefore, growth factors may predominantly act as differ-
entiating agents in some circumstances.
In CML, the characteristic fusion protein p210
bcr-abl pro-
longs G2-M (57, 58), and this effect on the cell cycle may be
responsible for selectively inducing differentiation in re-
sponse to GM-CSF. The association between cell cycle in-
hibition and cellular differentiation is well recognized; the
induction of differentiation of both normal and malignant
cells is associated with cell cycle inhibition that is mediated
by the inhibition of cdk activity and the induction of the cdk
inhibitors p21
cip1/waf1 and p27
kip1 (39). Furthermore, the ec-
topic expression of p21
cip1/waf1 and subsequent induction of
G1 cell cycle arrest induces the differentiation of U937 cells
(25, 59), whereas the inhibition of p21
cip1/waf1 blocks differ-
entiation (48). The inhibition of cell cycling may play an im-
portant role the activity of pharmacological differentiating
agents because most agents, such as ATRA, vitamin D, and
those examined in this study, share this biological property
despite interacting with a diverse array of cellular targets (25,
34, 60). Furthermore, standard chemotherapeutic agents,
such as ara-C and hydroxyurea, can also induce tumor cell
maturation when used at low concentrations that primarily
inhibit cell cycling rather than induce cell death, and their
ability to induce differentiation can be enhanced by growth
factors (35, 61). Our data suggest that pharmacological dif-
ferentiating agents and cytotoxic chemotherapeutic agents
used at cytostatic concentrations selectively enhance the
differentiating activity of growth factors by inhibiting cell
cycling and blocking the effects of growth factors on leuke-
mia cell proliferation. We found that blocking the cell cycle at
G1 (bryostatin-1 and phenylbutyrate) or S-phase (hydroxy-
urea) augmented growth factor-driven differentiation of AML
cells; thus, general slowing of cell cycle progression rather
than inhibition at a specific phase may be sufficient for this
process.
In contrast to its effects on AML cells, previous studies
have demonstrated that bryostatin-1 enhances the growth of
normal hematopoietic progenitors (7, 8). We found that the
combination of bryostatin-1 and GM-CSF also enhanced
the growth of normal hematopoietic progenitors. Moreover,
the other pharmacological differentiating agents tested also
had limited effects on normal hematopoietic progenitor
growth in combination with GM-CSF. A possible explanation
for the lack of normal marrow progenitor inhibition by these
combinations may be that progenitors are generally quies-
cent, residing in G0-G1 (62–64), and further delaying the cell
cycle may not alter their differentiation programs.
The goal of effective differentiation therapy is to promote
the maturation of tumor cells leading to the loss of self-
renewal capacity. The success of differentiation therapy in
the treatment of APL with ATRA has demonstrated that the
induction of tumor cell differentiation is a promising strategy
against AML (65). Unfortunately, the use of ATRA in APL has
remained the only clinical example of successful differentia-
tion therapy, although many pharmacological agents are ac-
tive in vitro (66). Our data indicate that the full induction of
terminal differentiation requires cell cycle inhibition com-
bined with lineage-specific growth factors. Therefore, the
clinical inactivity of pharmacological differentiating agents
may be attributable to inadequate levels of lineage-specific
growth factors. Accordingly, a recent report has described
the successful treatment of a patient with APL harboring the
atypical t(11;17) chromosomal translocation, which is nor-
mally refractory to ATRA, by combining ATRA with granulo-
cyte-CSF (67). Therefore, combining pharmacological differ-
entiating agents with exogenous growth factors may be
effective clinically, because this approach has potent antile-
ukemic activity while sparing normal hematopoiesis in vitro.
Materials and Methods
Cell Culture. The human AML cell lines, U937 and HL-60,
were obtained from American Type Culture Collection (Ma-
nassas, VA). Cells were maintained in RPMI 1640 (Life Tech-
nologies, Inc., Rockville, MD) supplemented with 7.5% heat-
inactivated FBS (Life Technologies, Inc.), 50 units/ml
penicillin, 50 g/ml streptomycin, and 2 mML -glutamine in a
humidified atmosphere at 37°C and 5.0% CO2. Cells in log-
arithmic phase were seeded at a density of 1  10
5 cells/ml
and incubated for 120 h with various concentrations of bryo-
statin-1 (National Cancer Institute, Bethesda, MD), hy-
droxyurea (Bristol Laboratories, Princeton, NJ), or phenylbu-
tyrate (National Cancer Institute) with or without recombinant
human GM-CSF (200 units/ml; Immunex, Seattle, WA).
Alternatively, cells were incubated as described above in
the presence of rat antihuman GM-CSF IgG2a (0.1 mg/ml)
and rat antihuman IL-3 IgG1 (0.15 mg/ml) antibodies (Phar-
Mingen, San Diego, CA). Nonbinding rat isotypic IgG2a and
IgG1 antibodies were used as controls (PharMingen), and
anti-growth factor or control antibodies were readded after
48 h of incubation. Clinical specimens were obtained from
patients with newly diagnosed AML or normal donors grant-
ing informed consent as approved by the Joint Commission
on Clinical Investigation of the Johns Hopkins Hospital.
Mononuclear cells were isolated from freshly harvested bone
marrow aspirates by density centrifugation (density, 1.078;
Ficoll-Paque, Pharmacia, Piscataway, NJ), followed by two
washes in MEM (Life Technologies, Inc.). For morphological
studies and cell surface antigen analysis, AML blasts were
further isolated using either antihuman CD34 or antihuman
CD33 antibodies coupled to magnetic microbeads (Miltenyi
Biotec, Auburn, CA), followed by magnetic column purifica-
tion (Miltenyi VarioMACS) according to the manufacturer’s
instructions (Miltenyi Biotec). Enriched fractions containing
95% leukemic cells (as measured by flow cytometry) were
obtained. For leukemia clonogenic assays, bone marrow
mononuclear cells were depleted of T cells with an antihu-
man CD3 antibody coupled to magnetic microbeads (Milte-
nyi Biotec).
Cell Cycle Analysis. After 48 h in culture with hydroxy-
urea, bryostatin-1, or phenylbutyrate, cell cycle distribution
280 Growth Factor-driven Differentiation of Myeloid Leukemiawas analyzed using BrdUrd and PI staining as described
previously (57). Briefly, cells (1  10
5) were washed with
complete medium and incubated at 37°C with 20 M BrdUrd
(Roche Molecular Biochemicals, Indianapolis, IN) for 60 min.
Cells were washed with PBS, fixed with ice-cold 70% etha-
nol, and digested for 30 min at room temperature with 0.2
mg/ml pepsin in 2 N HCl (Sigma, St. Louis, MO). Cells were
then labeled for 30 min at room temperature with FITC-
conjugated anti-BrdUrd antibody (Becton-Dickinson, Moun-
tain View, CA) in 0.5% Tween 20 (Bio-Rad, Hercules, CA).
After the removal of unbound anti-BrdUrd, the cells were
incubated in 5 g/ml DNase-free RNase (Roche Molecular
Biochemicals) and 25 M/ml PI (Sigma) for an additional 30
min at room temperature. Cell cycle distribution was ana-
lyzed using a FACScan flow cytometer (Becton Dickinson).
Determination of Apoptosis. Cells (1  10
5) were
washed with PBS, fixed in 70% ethanol, and resuspended in
0.1% Triton X-100 (Sigma) containing 5 g/ml DNase-free
RNase for 15 min at 37°C. Cells were then stained with 50
g/ml PI for 60 min at 4°C. The fraction of subdiploid cells
with oligonucleosomal DNA degradation characteristic of ap-
optosis was quantified by flow cytometric analysis as de-
scribed previously (57).
Clonogenic Assays. After 120 h of incubation, cells were
evaluated for clonogenic growth potential as described pre-
viously (54, 57, 68). Briefly, 200-1000 cells (for cell lines), 5 
10
4 cells (for bone marrow mononuclear cells from normal
donors), or 2  10
5 cells (for clinical AML samples) were
washed and placed in 1.0 ml of 1.2% methylcellulose, 30%
FBS, 1% BSA, 10
4 M 2-mercaptoethanol, and 2 ML -
glutamine containing 10% lymphocyte conditioned medium.
Samples were plated in quadruplicate onto 35-mm
2 tissue
culture dishes and incubated in a humidified atmosphere at
37°C and 5.0% CO2. Colonies consisting of 40 cells were
counted using an inverted microscope at 7 days for leukemia
colonies and 14 days for CFU-GM from normal bone mar-
row. Results are presented as the percentage of colonies
relative to the untreated controls  SE.
Cell Surface Antigen Expression. After 120 h of incuba-
tion, AML cell lines were analyzed for differentiation by ex-
amining the expression of the monocytic surface antigens
CD11b and CD14 by flow cytometry as described previously
(54) CD11b is the  subunit of the CD11b/CD18 het-
erodimeric complex involved in monocyte-endothelial cell
interaction; CD14 acts a monocyte receptor for lipopolysac-
charides (69, 70). Briefly, 1  10
5 cells were washed with
PBS containing 0.2% BSA. Staining was then performed
with FITC-conjugated mouse antihuman CD11b and phyco-
erythrin-conjugated mouse antihuman CD14 antibodies for
30 min at 4°C (Becton Dickinson). Cells were washed to
remove unbound antibody, fixed with 2% paraformaldehyde,
and evaluated by flow cytometry. Control studies were per-
formed with nonbinding mouse IgG1 and IgG2a isotype an-
tibodies (Becton Dickinson). Clinical AML specimens were
analyzed for evidence of myeloid differentiation by the sur-
face expression of CD15, using a FITC-conjugated mouse
antihuman CD15 IgM antibody (Becton Dickinson) or non-
binding FITC-conjugated mouse IgM isotype control anti-
body as described above. CD15 is a carbohydrate moiety
thought to be involved in neutrophil function (71). Results are
presented as the relative mean fluorescence intensity  SE
as described previously (72).
Statistical Analysis. Data are expressed as mean  SE.
Comparisons between treatments were performed using a
two-tailed, paired Student’s t test and ANOVA as indicated.
ANOVA was used to calculate the significance when com-
paring the means of all of the experimental groups during the
evaluation of a single variable (e.g., clonogenic growth or
relative mean fluorescence intensity). P  0.05 was consid-
ered significant.
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